Dendreon's (nasdaq: DNDN - news - people ) Provenge is a so-called cancer vaccine.
Dendreon ( DNDN - news - people ) that recently had good trial results.
Dendreon (nasdaq: DNDN - news - people )'s prostate cancer drug Provenge even though an advisory panel had voted to approve it.
But prominent cancer researchers have said the clinical trials Dendreon (nasdaq: DNDN - news - people ) conducted failed to prove Provenge helps patients.
Dendreon's (nasdaq: DNDN - news - people ) treatment, Provenge, failed in two clinical trials, but a second look at the data revealed a four-month survival benefit in one of them.
Dendreon (nasdaq: DNDN - news - people ) said today that it is planning to file an application with the Food and Drug Administration to have its cancer vaccine, Provenge, approved.
Apparently, experience doesn't count for everything: Aside from Gillis' problems with Bexxar, Henney is steering his current company, Dendreon (nasdaq: DNDN - news - people ), out of some recent disappointments over a prostate cancer vaccine.
Among the largest underlying components of XBI, in trading today Dendreon Corp ( NASD: DNDN) is up about 3.5%, Regeneron Pharmaceuticals, Inc. ( NASD: REGN) is up about 0.5%, and Incyte Corporation ( NASD: INCY) is higher by about 0.9%.
Among the largest underlying components of XBI, in trading today Dendreon Corp ( NASD: DNDN) is down about 2.9%, Regeneron Pharmaceuticals, Inc. ( NASD: REGN) is off about 0.1%, and Amylin Pharmaceuticals, Inc. ( NASD: AMLN) is lower by about 1.9%.
Among the largest underlying components of XBI, in trading today Isis Pharmaceuticals, Inc. ( NASD: ISIS) is off about 0.6%, Dendreon Corp ( NASD: DNDN) is down about 3.4%, and Seattle Genetics Inc ( NASD: SGEN) is lower by about 0.9%.
Dendreon (nasdaq: DNDN - news - people ) scored a surprise win last month when a panel of FDA advisers recommended that Provenge be approved to treat men whose prostate cancer has spread to other parts of the body.
Dendreon (DNDN) is expected to book a wider loss than a year ago when it reports third quarter earnings on Tuesday, October 30, 2012 with analysts expecting a loss of 83 cents per share, down from a loss of 67 cents per share a year ago.
应用推荐